Description
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathwaysIn VitroDA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoDA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus. DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission.Form:SolidIC50& Target:GLP-1/GIP